In order to offer the most cutting-edge technology for expression in mammalian cells, we acquired a licence for an innovative and proprietary CHO expression system.
Although we have a preference for IP-free technologies, we were convinced by the many attractive features of this CHO-Xpress system, which has proven to be an interesting tool for a variety of projects:
- Supply of therapeutic candidates for proof-of-concept or variant screening campaigns
- Production of recombinant monoclonal antibodies for analytic & diagnostic tool development
- Production of membrane target proteins for functional and structural characterization, screening studies, etc.
Production of virus-like particles for vaccine development
The CHO-Xpress technology combines the benefits of both transient and stable expression.
Homogeneous stable super-producer clones are obtained without cloning in just one week, whereas classical generation of stable cell lines takes 6 to 9 months. The obtained cell lines can be banked and re-used for further productions. Whereas transient transfection is very expensive at large scale, we are able to offer, with the CHO-Xpress technology, attractive cost reductions with scale-up.
When compared to classical production methods, this technology has proven its efficacy in achieving high production yields for various protein types:
We offer to evaluate the CHO-Xpress system in a short time
To evaluate the CHO-Xpress system for your specific protein or antibody, we offer our feasibility study service which includes the generation of the cell line and a small-scale expression and purification trial in order to determine the production yield and obtain a protein test batch for your validation. This material can be delivered in just two months (a few additional weeks will be necessary if gene synthesis is required).
We are then able to easily and quickly provide gram amounts of proteins or antibodies for your studies.